The company will start a phase 2/3 trial of PF-08634404 in March.
ApexOnco Front Page
Recent articles
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
The French group takes a shot at Perspective with its second bet on Orano Med.
The Hutchmed-originated savolitinib moves towards its first US approval.
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
